Clinical Trial Detail

NCT ID NCT01357161
Title A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

ovarian cancer

fallopian tube cancer

peritoneal carcinoma

Therapies

Carboplatin

Adavosertib

Paclitaxel

Age Groups: adult senior

No variant requirements are available.